The Honorable Craig StapletonAmbassador Stapleton served the United States as Ambassador to France from 2005 until 2009 after having served as the United States Ambassador to Prague. Ambassador Stapleton served as President of Marsh and McLennan Real Estate Advisors of New York from 1982 until 2001. He has served on the board of directors for several companies including Allegheny Properties, Metro PCS, TB Woods and Winston Partners. He was a part owner of the Texas Rangers baseball team from 1989-1998 and is currently a part owner of the St. Louis Cardinals. Ambassador Stapleton is currently serving as a Trustee of the George W. Bush Library and Foundation, the 9/11 Memorial Foundation, the de Tocqueville/United Way Foundation, CERGE (the Center for Economic Research and Graduate Education), and the Association François-Xavier Bagnoud. He has served on the Visiting Committee for Harvard College and the Committee on University Resources. Ambassador Stapleton is President of the Vaclav Havel Foundation in the United States. He currently serves as a Senior Advisor to Stone Point Capital and is the lead director of Abercrombie and Fitch. He received his B.A. (magna cum laude) from Harvard University and his M.B.A. from Harvard Business School. “We are extremely proud that people of such quality have accepted to join our Board,” said Elie Vannier, the chairman of the Board of Directors of Flamel Technologies. “They offer an impressive and new set of skills to an already highly distinguished independent board of directors, which includes Mr. Lodewijk deVink, Dr. Frank JT Fildes, and Mr. John Vogelstein. We also wish to thank Mr. Lemoine for his service to the Company over the past six years. We deeply regret that his new prominent professional position does not allow him to remain a Flamel director.”
Stephen H. Willard, Flamel’s chief executive officer added: “Our board will benefit from the extensive backgrounds of our proposed three new board members. I am grateful for the expertise that each of them brings to Flamel, and am honored that each should accept to serve on our Board of Directors. I believe that it is a great vote of confidence for Flamel that we should attract such strong board members and am looking forward to working with them in the years to come.”Mr. Willard continued: “I also wish to thank Mr. Lemoine for his years of service to Flamel. His contributions were very significant to our company’s development.” About Flamel Flamel Technologies SA (NASDAQ: FLML) is a leading drug delivery company focused on the goal of developing safer, more efficacious formulations of drugs that address unmet medical needs. Its product development pipeline includes biological and chemical drugs formulated with the Medusa® and Micropump® proprietary platforms. Several Medusa- based products are at various clinical stages of development; Medusa’s lead internal product candidate IFN-alpha XL (long-acting interferon alpha-2b) is currently the subject of a Phase 2 trial in HCV patients. The Company has developed approved products and manufactures Micropump-based microparticles. Flamel Technologies has collaborations with a number of leading pharmaceutical and biotechnology companies, including Baxter, GlaxoSmithKline, Merck Serono and Pfizer. Additional information can be found at www.flamel.com. This document contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including certain plans, expectations, goals and projections regarding financial results, product developments and technology platforms. All statements that are not clearly historical in nature are forward-looking, and the words “anticipate,” “assume,” “believe,” “expect,” “estimate,” “plan,” will,” and similar expressions are generally intended to identify forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, that could cause actual results to differ materially from those contemplated in such forward-looking statements. These risks include risks that products in the development stage may not achieve scientific objectives or milestones or meet stringent regulatory requirements, uncertainties regarding market acceptance of products in development, the impact of competitive products and pricing, and the risks associated with Flamel's reliance on outside parties and key strategic alliances. These and other risks are described more fully in Flamel's Annual Report on the Securities and Exchange Commission Form 20-F for the year ended December 31, 2009. All forward-looking statements included in this release are based on information available at the time of the release. We undertake no obligation to update or alter our forward-looking statements as a result of new information, future events or otherwise.